Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Tai
Cheng-Jeng
CJ
Section of Hematology-Oncology, Taipei Medical University Hospital and Department of Medicine, Taipei Medical University, Taipei, Taiwan. cjtai@tmu.edu.tw
D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage; D016879:Salvage Therapy; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D014747:Vinblastine; D000077157:Sorafenib; D005472:Fluorouracil